Ardent is developing a pipeline of biosimilars that will be presented to the authorities without the execution of a Clinical Efficacy Study (phase III). The MHRA, FDA and EMA have already announced the willingness to waive a phase III trial for applications with thorough scientific evidence showing that all critical quality attributes fall within the variability of the reference product. Development costs will decline dramatically giving Ardent a first mover advantage.